Skip to main content
PMC home page
Heart logoLink to Heart
. 1996 Aug;76(2):129–136. doi: 10.1136/hrt.76.2.129

Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.

W Friedl 1, J Mair 1, S Thomas 1, M Pichler 1, B Puschendorf 1
PMCID: PMC484459  PMID: 8795474

Abstract

BACKGROUND: Screening for patients with asymptomatic left ventricular dysfunction is of considerable importance because they may benefit from early treatment with angiotensin converting enzyme inhibitors. It has been suggested that atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and cyclic guanosine 3',5'-monophosphate (cGMP) might be useful markers for screening. OBJECTIVE: To compare directly the power of the three immunoreactive forms of ANP (CT-ANP, beta-ANP, NT-ANP) and BNP and cGMP to detect asymptomatic left ventricular dysfunction. METHODS AND RESULTS: Radionuclide ventriculography was used to study left ventricular ejection fraction in 37 patients with asymptomatic left ventricular dysfunction, 32 patients with mild to moderate congestive heart failure, and 38 controls. CT-ANP, NT-ANP, beta-ANP, BNP, and cGMP were measured at rest and 3 minutes after exercise. Plasma BNP was the most sensitive marker for patients with asymptomatic left ventricular dysfunction but it reached only a sensitivity of 58% and a specificity of 76% at rest and a sensitivity of 65% and a specificity of 84% after exercise. Combined measurements of all natriuretic peptides and cGMP did not improve the power to detect asymptomatic left ventricular function above that of a single BNP measurement. CONCLUSIONS: Although natriuretic peptides and cGMP measured at rest and three minutes after ergometry may be useful for monitoring left ventricular dysfunction they are unlikely to be suitable for more general routine screening for completely asymptomatic left ventricular dysfunction.

Full text

PDF
129

Images in this article

136Image
on p.136

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandt R. R., Wright R. S., Redfield M. M., Burnett J. C., Jr Atrial natriuretic peptide in heart failure. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):86A–92A. doi: 10.1016/0735-1097(93)90468-g. [DOI] [PubMed] [Google Scholar]
  2. Burnett J. C., Jr, Kao P. C., Hu D. C., Heser D. W., Heublein D., Granger J. P., Opgenorth T. J., Reeder G. S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986 Mar 7;231(4742):1145–1147. doi: 10.1126/science.2935937. [DOI] [PubMed] [Google Scholar]
  3. Caidahl K., Hedner J., Hedner T. Atrial natriuretic peptide and catecholamines in peripheral blood as indicators of cardiac dysfunction in the general population. Clin Sci (Lond) 1988 Jun;74(6):587–594. doi: 10.1042/cs0740587. [DOI] [PubMed] [Google Scholar]
  4. Choy A. M., Darbar D., Lang C. C., Pringle T. H., McNeill G. P., Kennedy N. S., Struthers A. D. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994 Jul;72(1):16–22. doi: 10.1136/hrt.72.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edwards B. S., Zimmerman R. S., Schwab T. R., Heublein D. M., Burnett J. C., Jr Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988 Feb;62(2):191–195. doi: 10.1161/01.res.62.2.191. [DOI] [PubMed] [Google Scholar]
  6. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–1729. doi: 10.1161/01.cir.82.5.1724. [DOI] [PubMed] [Google Scholar]
  7. Gottlieb S. S., Kukin M. L., Ahern D., Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989 Jun;13(7):1534–1539. doi: 10.1016/0735-1097(89)90344-6. [DOI] [PubMed] [Google Scholar]
  8. Hall C., Kjekshus J., Eneroth P., Snapinn S. The plasma concentration of N-terminal proatrial natriuretic factor ANF(1-98) is related to prognosis in severe heart failure. Clin Cardiol. 1994 Apr;17(4):191–195. doi: 10.1002/clc.4960170409. [DOI] [PubMed] [Google Scholar]
  9. Hall C., Rouleau J. L., Moyè L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M. O. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994 May;89(5):1934–1942. doi: 10.1161/01.cir.89.5.1934. [DOI] [PubMed] [Google Scholar]
  10. Haug C., Metzele A., Kochs M., Hombach V., Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993 Jul;16(7):553–557. doi: 10.1002/clc.4960160708. [DOI] [PubMed] [Google Scholar]
  11. Hirata Y., Ishii M., Matsuoka H., Sugimoto T., Iizuka M., Uchida Y., Serizawa T., Sato H., Kohmoto O., Mochizuki T. Plasma concentrations of alpha-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am Heart J. 1987 Jun;113(6):1463–1469. doi: 10.1016/0002-8703(87)90663-6. [DOI] [PubMed] [Google Scholar]
  12. Jakob G., Mair J., Pichler M., Puschendorf B. Ergometric exercise testing and sensitivity of cyclic guanosine 3',5'-monophosphate (cGMP) in diagnosing asymptomatic left ventricular dysfunction. Br Heart J. 1995 Feb;73(2):145–150. doi: 10.1136/hrt.73.2.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jakob G., Mair J., Vorderwinkler K. P., Judmaier G., König P., Zwierzina H., Pichler M., Puschendorf B. Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure. Clin Chem. 1994 Jan;40(1):96–100. [PubMed] [Google Scholar]
  14. Lang C. C., Choy A. M., Struthers A. D. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci (Lond) 1992 Nov;83(5):519–527. doi: 10.1042/cs0830519. [DOI] [PubMed] [Google Scholar]
  15. Lerman A., Gibbons R. J., Rodeheffer R. J., Bailey K. R., McKinley L. J., Heublein D. M., Burnett J. C., Jr Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet. 1993 May 1;341(8853):1105–1109. doi: 10.1016/0140-6736(93)93125-k. [DOI] [PubMed] [Google Scholar]
  16. Metz C. E. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol. 1989 Mar;24(3):234–245. doi: 10.1097/00004424-198903000-00012. [DOI] [PubMed] [Google Scholar]
  17. Motwani J. G., McAlpine H., Kennedy N., Struthers A. D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993 May 1;341(8853):1109–1113. doi: 10.1016/0140-6736(93)93126-l. [DOI] [PubMed] [Google Scholar]
  18. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., Shirakami G., Jougasaki M., Obata K., Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991 Apr;87(4):1402–1412. doi: 10.1172/JCI115146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992 Jul 11;340(8811):88–92. doi: 10.1016/0140-6736(92)90405-r. [DOI] [PubMed] [Google Scholar]
  20. Rosenzweig A., Seidman C. E. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem. 1991;60:229–255. doi: 10.1146/annurev.bi.60.070191.001305. [DOI] [PubMed] [Google Scholar]
  21. Song D. L., Kohse K. P., Murad F. Brain natriuretic factor. Augmentation of cellular cyclic GMP, activation of particulate guanylate cyclase and receptor binding. FEBS Lett. 1988 May 9;232(1):125–129. doi: 10.1016/0014-5793(88)80400-9. [DOI] [PubMed] [Google Scholar]
  22. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  23. Tsutamoto T., Kanamori T., Morigami N., Sugimoto Y., Yamaoka O., Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation. 1993 Jan;87(1):70–75. doi: 10.1161/01.cir.87.1.70. [DOI] [PubMed] [Google Scholar]
  24. Vorderwinkler K. P., Artner-Dworzak E., Jakob G., Mair J., Diensti F., Pichler M., Puschendorf B. Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases. Clin Chem. 1991 Feb;37(2):186–190. [PubMed] [Google Scholar]
  25. Wallén T., Landahl S., Hedner T., Hedner J., Hall C. Atrial peptides, ANP(1-98) and ANP(99-126) in health and disease in an elderly population. Eur Heart J. 1993 Nov;14(11):1508–1513. doi: 10.1093/eurheartj/14.11.1508. [DOI] [PubMed] [Google Scholar]
  26. Wei C. M., Heublein D. M., Perrella M. A., Lerman A., Rodeheffer R. J., McGregor C. G., Edwards W. D., Schaff H. V., Burnett J. C., Jr Natriuretic peptide system in human heart failure. Circulation. 1993 Sep;88(3):1004–1009. doi: 10.1161/01.cir.88.3.1004. [DOI] [PubMed] [Google Scholar]
  27. Wei C. M., Kao P. C., Lin J. T., Heublein D. M., Schaff H. V., Burnett J. C., Jr Circulating beta-atrial natriuretic factor in congestive heart failure in humans. Circulation. 1993 Sep;88(3):1016–1020. doi: 10.1161/01.cir.88.3.1016. [DOI] [PubMed] [Google Scholar]
  28. Winters C. J., Sallman A. L., Baker B. J., Meadows J., Rico D. M., Vesely D. L. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation. 1989 Sep;80(3):438–449. doi: 10.1161/01.cir.80.3.438. [DOI] [PubMed] [Google Scholar]
  29. Yasue H., Obata K., Okumura K., Kurose M., Ogawa H., Matsuyama K., Jougasaki M., Saito Y., Nakao K., Imura H. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest. 1989 Jan;83(1):46–51. doi: 10.1172/JCI113883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES